MACITENTAN (Opsumit)

Clinical Indication

For long-term treatment of pulmonary arterial hypertension in paediatric patients aged 2 years to less than 18 years with WHO Functional Class II to III

Date of classification

June 2025

Grey

Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.

  • New medicines, devices, appliances.
  • New indication of existing medicine.
  • New NICE TA which has not been reviewed.
  • Not been requested for review by either TAS/LPT MMC.